JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265671

Human RNF149 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

RNF149 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

DNA polymerase-transactivated protein 2, DNAPTP2, E3 ubiquitin-protein ligase RNF149, RING finger protein 149, RN149_HUMAN, Rnf149

2 Images
Sanger Sequencing - Human RNF149 knockout HeLa cell line (AB265671)
  • Sanger seq

Unknown

Sanger Sequencing - Human RNF149 knockout HeLa cell line (AB265671)

Allele-2 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human RNF149 knockout HeLa cell line (AB265671)
  • Sanger seq

Unknown

Sanger Sequencing - Human RNF149 knockout HeLa cell line (AB265671)

Allele-1 : 1 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265671-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265671 Human RNF149 knockout HeLa cell line", "number":"AB265671-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265671-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265671-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265671-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265671 Human RNF149 knockout HeLa cell line", "number":"AB265671-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265671-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265671 Human RNF149 knockout HeLa cell line", "number":"AB265671-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265671-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265671 Human RNF149 knockout HeLa cell line", "number":"AB265671-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
RNF149
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RNF149 also known as RING Finger Protein 149 is an E3 ubiquitin-protein ligase which means it catalyzes the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to a substrate protein tagging it for degradation. The mass of RNF149 is approximately 49 kDa. It can be found expressed in various tissues with notable presence in the liver and kidney. This protein contains a RING-type zinc finger domain which is critical for its ligase activity and substrate specificity.
Biological function summary

RNF149 participates in protein quality control by mediating the ubiquitination of proteins that require degradation therefore maintaining protein homeostasis. It acts independently and is not part of a larger protein complex. By tagging damaged or misfolded proteins for degradation RNF149 contributes to the cellular stress response ensuring that cells respond to potential stressors effectively and efficiently.

Pathways

The involvement of RNF149 in the ubiquitin-proteasome system places it within the protein degradation pathway which is essential for regulating protein turnover and cellular function. It interacts with several other proteins including ubiquitin-conjugating enzyme E2s in this pathway. RNF149 may also intersect with apoptosis pathways due to its role in controlling the degradation of apoptotic regulators linking it to proteins involved in cell death processes.

RNF149 shows a connection to certain cancers and neurodegenerative diseases. Abnormal expression or mutations in RNF149 can relate to the deregulation of protein turnover contributing to the development of hepatocellular carcinoma. It is also connected to neurodegenerative disorders due to its role in degrading damaged proteins with connections to proteins like p53 in cancer pathways and tau proteins in neurological contexts.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com